The future of multiple sclerosis therapy

Bernd C. Kieseier, Heinz Wiendl, Hans Peter Hartung, Olaf Stüve

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity. A better understanding of the immunopathological processes underlying this disease have recently led to the design of numerous novel therapeutical approaches. Perhaps most importantly, therapy has changed dramatically over the past decade in that all relapsing forms of MS, including early forms of MS are now being treated relatively aggressively. However, there are still unmet needs in the management of this disease, especially since all of the currently available disease-modifying drugs are only partially effective. Most of the clinically relevant therapeutic agents are not yet available as oral formulations. A substantial number of pivotal and preliminary reports provide encouraging new evidence on advances being made in the development of oral therapies for MS. A different strategy is the development of very potent monoclonal antibodies, given intravenously or subcutaneously, many of which are being examined for clinical efficacy. These agents are potentially more effective, but may carry more serious side effects. Finally, drugs with a known good safety profile are being developed further. These advances are critically reviewed and put into perspective.

Original languageEnglish (US)
Pages (from-to)207-211
Number of pages5
JournalPharmacological Research
Volume60
Issue number4
DOIs
StatePublished - Oct 2009

Fingerprint

Multiple Sclerosis
Autoimmune Diseases of the Nervous System
Therapeutics
Disease Management
Pharmaceutical Preparations
Young Adult
Monoclonal Antibodies
Safety

Keywords

  • Immunomodulation
  • Immunosuppression
  • Injectables
  • Multiple sclerosis
  • Oral therapy

ASJC Scopus subject areas

  • Pharmacology

Cite this

The future of multiple sclerosis therapy. / Kieseier, Bernd C.; Wiendl, Heinz; Hartung, Hans Peter; Stüve, Olaf.

In: Pharmacological Research, Vol. 60, No. 4, 10.2009, p. 207-211.

Research output: Contribution to journalArticle

Kieseier, Bernd C. ; Wiendl, Heinz ; Hartung, Hans Peter ; Stüve, Olaf. / The future of multiple sclerosis therapy. In: Pharmacological Research. 2009 ; Vol. 60, No. 4. pp. 207-211.
@article{b6d96bf38855408bb6851b8ff338f263,
title = "The future of multiple sclerosis therapy",
abstract = "Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity. A better understanding of the immunopathological processes underlying this disease have recently led to the design of numerous novel therapeutical approaches. Perhaps most importantly, therapy has changed dramatically over the past decade in that all relapsing forms of MS, including early forms of MS are now being treated relatively aggressively. However, there are still unmet needs in the management of this disease, especially since all of the currently available disease-modifying drugs are only partially effective. Most of the clinically relevant therapeutic agents are not yet available as oral formulations. A substantial number of pivotal and preliminary reports provide encouraging new evidence on advances being made in the development of oral therapies for MS. A different strategy is the development of very potent monoclonal antibodies, given intravenously or subcutaneously, many of which are being examined for clinical efficacy. These agents are potentially more effective, but may carry more serious side effects. Finally, drugs with a known good safety profile are being developed further. These advances are critically reviewed and put into perspective.",
keywords = "Immunomodulation, Immunosuppression, Injectables, Multiple sclerosis, Oral therapy",
author = "Kieseier, {Bernd C.} and Heinz Wiendl and Hartung, {Hans Peter} and Olaf St{\"u}ve",
year = "2009",
month = "10",
doi = "10.1016/j.phrs.2009.03.016",
language = "English (US)",
volume = "60",
pages = "207--211",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - The future of multiple sclerosis therapy

AU - Kieseier, Bernd C.

AU - Wiendl, Heinz

AU - Hartung, Hans Peter

AU - Stüve, Olaf

PY - 2009/10

Y1 - 2009/10

N2 - Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity. A better understanding of the immunopathological processes underlying this disease have recently led to the design of numerous novel therapeutical approaches. Perhaps most importantly, therapy has changed dramatically over the past decade in that all relapsing forms of MS, including early forms of MS are now being treated relatively aggressively. However, there are still unmet needs in the management of this disease, especially since all of the currently available disease-modifying drugs are only partially effective. Most of the clinically relevant therapeutic agents are not yet available as oral formulations. A substantial number of pivotal and preliminary reports provide encouraging new evidence on advances being made in the development of oral therapies for MS. A different strategy is the development of very potent monoclonal antibodies, given intravenously or subcutaneously, many of which are being examined for clinical efficacy. These agents are potentially more effective, but may carry more serious side effects. Finally, drugs with a known good safety profile are being developed further. These advances are critically reviewed and put into perspective.

AB - Multiple sclerosis (MS) represents the prototypic inflammatory autoimmune disorder of the central nervous system and the most common cause of neurological disability in young adults, exhibiting considerable clinical, radiological and pathological heterogeneity. A better understanding of the immunopathological processes underlying this disease have recently led to the design of numerous novel therapeutical approaches. Perhaps most importantly, therapy has changed dramatically over the past decade in that all relapsing forms of MS, including early forms of MS are now being treated relatively aggressively. However, there are still unmet needs in the management of this disease, especially since all of the currently available disease-modifying drugs are only partially effective. Most of the clinically relevant therapeutic agents are not yet available as oral formulations. A substantial number of pivotal and preliminary reports provide encouraging new evidence on advances being made in the development of oral therapies for MS. A different strategy is the development of very potent monoclonal antibodies, given intravenously or subcutaneously, many of which are being examined for clinical efficacy. These agents are potentially more effective, but may carry more serious side effects. Finally, drugs with a known good safety profile are being developed further. These advances are critically reviewed and put into perspective.

KW - Immunomodulation

KW - Immunosuppression

KW - Injectables

KW - Multiple sclerosis

KW - Oral therapy

UR - http://www.scopus.com/inward/record.url?scp=69249202564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249202564&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2009.03.016

DO - 10.1016/j.phrs.2009.03.016

M3 - Article

C2 - 19717009

AN - SCOPUS:69249202564

VL - 60

SP - 207

EP - 211

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -